Aspire Biopharma, Inc. Engages CTM Advisory, Ltd., and Receives Advisory Engagement from Spartan Capital Securities, LLC to Explore NASDAQ Listed Company Merger

HUMACAO, PR, March 20, 2024 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the engagement of CTM Advisory, Ltd. and has received an advisory engagement and expects to engage Spartan Capital Securities, LLC to manage the merger transaction.

CTM Advisory, has been engaged by Aspire, to use its expertise and relationships to identify, negotiate, and lead the process with selected strategic opportunities, including Nasdaq Global Market operating companies that are considering and seeking market ready growth companies to merge as successor operating business enterprises.  Aspire has been identified as one of these sought after high growth unique Biotech technology firms.  Spartan Capital Securities, a global FINRA/SIPC, Broker Dealer and Investment Bank, headquartered in New York City, is expected to advise Aspire on the proposed merger transaction and other capital markets transactions post-merger.

Kraig Higginson, CEO, stated, “we are excited to have CTM working with us as we endeavor to bring our new drug delivery mechanism to the biotech industry.  By exploring our opportunities to move into the NASDAQ Market System, we look to grow our shareholder value, and take advantage of the strong US Capital Markets.”

“Aspire’s delivery system has the potential to change the way many already approved FDA drugs, peptides and other treatments and supplements are transferred into the blood stream, versus the typical delivery methods like injections or swallowing pills.  We look forward to CTM providing us the expertise and experience they have in selecting a well qualified NASDAQ global market company.”

Shawn Mesaros, Managing Member, stated “Aspire BioPharma’s commitment to addressing unmet medical needs and improving FDA medications through delivery based upon a strong scientific foundation convinced me that this Company is poised for growth”.  

About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time.  For more information, please visit

Safe Harbor Statement. Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Aspire Biopharma, Inc. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company’s actual results to differ materially from those contained in these forward-looking statements can be found in the Company’s Form CF and Form D, filed with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether because of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.